Quick Answer
RHYTHM PHARMACEUTICALS, INC. reported Long-Term Debt of $100.89 million for fiscal year 2025.
RHYTHM PHARMACEUTICALS, INC. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $100.89M | -6.8% |
| 2024 | $108.27M | +2.0% |
| 2023 | $106.14M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $103.41M | — | -2.5% |
| June 30, 2025 | $106.01M | — | -1.8% |
| March 31, 2025 | $107.93M | — | -0.3% |
| December 31, 2024 | $108.27M | — | +48.4% |
| September 30, 2022 | $72.96M | — | +112.9% |
| June 30, 2022 | $34.27M | — | — |
- RHYTHM PHARMACEUTICALS, INC. showed a decrease of -6.8% in Long-Term Debt compared to the prior fiscal year.
- Over the 2023–2025 period, RHYTHM PHARMACEUTICALS, INC.’s long-term debt has declined by 5.0% (from $106.14 million to $100.89 million).
- The most recent figure is from RHYTHM PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: